Invited Speakers for ICLAF 2018 Scientific Sessions LECTURE SPEAKER INSTITUTION CLINICAL RESEARCH A Pathway Toward Prevention of Lederer Columbia University Pulmonary Fibrosis Location, Location, Location: Kerri Johannson University of Calgary Geography Informs Trajectory in Fibrotic ILD Combined Pulmonary Fibrosis and Vincent Cottin University of Lyon Emphysema: Where We Have Been and Where We Are Going Pragmatic Trials When, Why, and – Kevin Anstrom Duke University How Catholic University of IPF: Considerations for Future Trials Luca Richeldi the Sacred Heart IPF and Rheumatoid Arthritis University of Denver Joyce Lee Associated ILD Is There a – Colorado Connection? BASIC The Non-sterol Mevalonate Pathway: Brent Carter University of Alabama Progressive Fibrotic Repair in the Absence of Injury The ADAM10-Sephrin-B2 Pathway in David Lagares Harvard University Lung Fibrosis: Mechanistic Insights and Therapeutic Opportunities University of California Toward Precision Medicine in Fibrotic Harold Chapman San Francisco Lung Disease PAMPS vs. DAMPS: Innate Immunity Erica Herzog Yale University in IPF University of Colorado Wnt Signaling in Lung Repair and Melanie Koenigshoff Denver Fibrosis Mechanical and Epithelial Influences Dan Tschumperlin Mayo Clinic on Fibroblast Activation TRANSLATIONAL Mitochondria and Metabolic University of Pittsburgh Ana Mora Alterations at the Crossroad of Aging Medical Center and Lung Fibrosis Metabolic Disorders in Pulmonary Argyrios Tzouvelekis University of Athens Fibrosis In light of Hormone – Replacement Therapy Pneumonitis and Fibrosis Post-Stem Beth Moore University of Michigan Cell Transplant: Host and Microbial Influences University of Targeting and Profiling Molecular Jenkins Nottingham Endotypes of Pulmonary Fibrosis Translating Human Genetic University of Texas Christine Garcia Discoveries in Pulmonary Fibrosis to Southwestern Clinical Care Therapeutic Targeting of University of Arizona Pathologic Mechanisms in Louise Hecker Pulmonary Fibrosis
Invited Speakers for ICLAF 2018 Scientific Sessions SPEAKER INSTITUTION LECTURE CLINICAL RESEARCH Lederer Columbia University A Pathway Toward Prevention of Pulmonary Fibrosis Kerri Johannson University of Calgary Location, Location, Location: Geography Informs Trajectory in Fibrotic ILD Vincent Cottin University of Lyon Combined Pulmonary Fibrosis and Emphysema: Where We Have Been and Where We Are Going Kevin Anstrom Duke University Pragmatic Trials – When, Why, and How Luca Richeldi Catholic University of the Sacred Heart IPF: Considerations for Future Trials Joyce Lee University of Denver Colorado IPF and Rheumatoid Arthritis Associated ILD – Is There a Connection? BASIC Brent Carter University of Alabama The Non-sterol Mevalonate Pathway: Progressive Fibrotic Repair in the Absence of Injury David Lagares Harvard University The ADAM10-Sephrin-B2 Pathway in Lung Fibrosis: Mechanistic Insights and Therapeutic Opportunities Harold Chapman University of California San Francisco Toward Precision Medicine in Fibrotic Lung Disease Erica Herzog Yale University PAMPS vs. DAMPS: Innate Immunity in IPF Melanie Koenigshoff University of Colorado Denver Wnt Signaling in Lung Repair and Fibrosis Dan Tschumperlin Mayo Clinic Mechanical and Epithelial Influences on Fibroblast Activation TRANSLATIONAL Ana Mora University of Pittsburgh Medical Center Mitochondria and Metabolic Alterations at the Crossroad of Aging and Lung Fibrosis Argyrios Tzouvelekis University of Athens Metabolic Disorders in Pulmonary Fibrosis – In light of Hormone Replacement Therapy Beth Moore University of Michigan Pneumonitis and Fibrosis Post-Stem Cell Transplant: Host and Microbial Influences Jenkins University of Nottingham Targeting and Profiling Molecular Endotypes of Pulmonary Fibrosis Christine Garcia University of Texas Southwestern Translating Human Genetic Discoveries in Pulmonary Fibrosis to Clinical Care Louise Hecker University of Arizona Therapeutic Targeting of Pathologic Mechanisms in Pulmonary Fibrosis